Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL
Status:
RECRUITING
Trial end date:
2028-08-01
Target enrollment:
Participant gender:
Summary
Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive lymphoma. At present, the treatment of new diagnosed AITL has limited efficacy and a high recurrence rate. The study seeks to explore the possibility of improving the efficacy of immunotherapy and chemotherapy and epigenetically regulated drugs.
Phase:
PHASE2
Details
Lead Sponsor:
The Affiliated Hospital of Xuzhou Medical University